The top five brands in the retail market of rhinitis drugs are stable and foreign capital still dominates

　　Medical News, May 31st.
While my country's industry continues to accelerate development, the environment continues to deteriorate.
There are reports that less than 1% of China's 500 large cities meet the air quality standards recommended by the World Health Organization.
There are more than 300 million patients with rhinitis in my country, the incidence of rhinitis is as high as 37%, and the number of patients is increasing at a rate of 3% every year, which brings huge space for the development of the rhinitis drug market.

 

　　The epidemic eases and the market growth momentum is strong

 

　　According to data from the terminal competition pattern of physical pharmacies in key cities of Minai.
com, the rhinitis drug market in Nanjing, Qingdao, and Wuhan from 2016 to 2019 has shown a steady growth trend.
Due to the epidemic in 2020, people will wear masks for a long time to reduce going out.
, Part of the factors that cause rhinitis are isolated, such as dust mites, pollen, catkins, etc.
, and the demand for drugs for patients with rhinitis is relatively reduced.
The growth momentum of the rhinitis medicine market in Nanjing and Wuhan will ease in 2020, especially in Wuhan, which is most affected by the epidemic.
Qingdao has a maritime monsoon climate, and the incidence of allergic rhinitis in Qingdao is as high as 15%, the increase in patient demand for medication has made the market size rise instead of falling.

 

　　Figure 1: 2016-2020 sales trend of rhinitis drugs in three cities (unit: ten thousand yuan)

 

　　Chemical drugs climb all the way and become the protagonist of the market

 

　　In the rhinitis drug market, proprietary Chinese medicines were once popular with patients due to their low side effects and mild efficacy.
In recent years, as the pace of life has accelerated and acute attacks of rhinitis have become more frequent, chemical drugs that are convenient to carry and have obvious effects have gradually become the main force in the market.
Data show that in 2016, the market share of Chinese patent medicines in the above three cities was 6 percentage points higher than the market share of chemical medicines.
In the following years, the status of Chinese patent medicines was threatened and gradually weakened.
Chemical medicines became more and more favored by patients, and their market share gradually increased.
By 2020, chemical drugs will account for 55% of the market share, an increase of 8 percentage points from 2016, and seize the leading position in the market.

 

　　Figure 2: The proportion of Chinese patent medicines and chemical medicines used for rhinitis in the three cities from 2016 to 2020

 

　　Convenient to carry, direct to the affected area, inhalers dominate

 

　　In terms of the dosage form, there are only 8 dosage forms of rhinitis medicines.
In 2020, the rhinitis medicine market in Nanjing, Qingdao, and Wuhan will be divided into three parts: inhalants, oral medicines, and external medicines, accounting for 56%, 41% and 3% respectively.
%.
Among them, inhalation dosage forms composed of aerosols, sprays and powder mists are the best.
Because of their simple use, convenient carrying, local inhalation medication directly to the affected area, rapid relief of symptoms, etc.
, they have become the preferred dosage form for patients with rhinitis.
Inhalants have gradually expanded the market since 2016, and have occupied 54% of the market share by 2020, with a solid leading position.
Oral preparations are led by tablets, with a market share of about 20% in the past five years.
Other dosage forms have shown a gradual decline due to the overwhelming momentum of inhalants.
External dosage forms such as nasal drops and nasal ointment only occupy a small share in the market.

 

　　Figure 3: The proportion of rhinitis drugs in the three cities from 2016 to 2020

 

　　The top five brands are stable, and foreign brands dominate the market

 

　　From 2016 to 2020, the top five brands of rhinitis drugs in the three cities are stable, with slight changes in ranking.
The top two steadily occupying the top two are foreign brands, both of which are glucocorticoid nasal sprays.
In 2020, the two together account for 28.
3% of the market share.
The fluticasone propionate nasal spray (Fushuliang) produced by GlaxoSmithKline is popular among patients due to its strong anti-inflammatory activity and unique preparation form, which directly hits the affected area, has unique curative effect and small side effects, and is popular among patients.
.
The second is budesonide nasal spray (Reynoldscot) produced by AstraZeneca, which has been catching up in recent years, with a strong momentum and a promising future.
Merck's mometasone furoate nasal spray (Nesuna) also gradually climbed from the fifth place in 2016, and won the third place for two consecutive years starting in 2019.

 

　　The domestic brands that originally performed well in the market, Sinopharm Dezhong Pharmaceutical's Biyankang Tablets and Hubei Yuanda Tiantianming Pharmaceutical's Xilozoline Hydrochloride Nasal Spray, have gradually declined in the market competition and missed the top three.
It is worth noting that four of the top five brands are chemical nasal spray formulations, and Biyankang tablets are the only Chinese patent medicine that ranks in the top five.

 

　　Figure 4: 2016-2020 trend of changes in the share of the top five brands of rhinitis drugs in the three cities

 

　　In the rhinitis drug market in the three cities of Nanjing, Qingdao and Wuhan, chemical drugs are leading the market and are singing all the way.
Compared with chemical medicines, proprietary Chinese medicines have a complicated category, which dazzles patients with rhinitis when choosing medications.
However, Biyankang tablets have made a breakthrough in the rhinitis medication market by virtue of a variety of marketing advertisements and a good reputation for medicinal effects.
Therefore, brand effect is the key point that manufacturers need to grasp in the market competition of rhinitis drugs.
Only when the brand effect is maximized, can it become the patient's favorite choice when purchasing drugs.

 

　　Source: Mi Nei Net Database

 

　　Note: The terminal competition pattern of physical pharmacies in key cities of Minai.
com is based on the sales data of all physical pharmacies in 22 key cities, including Beijing, Shanghai, Guangzhou, and Shenzhen, and is a sample city drug database that continuously monitors all categories.
The above sales are calculated based on the average retail price of the product at the terminal.